The Rapidly Evolving Treatment Landscape in PIK3CA-mutated HR+ HER2- Breast Cancer
Panelists discuss how the evolving landscape of targeted therapies for PIK3CA-mutated HR+ HER2- breast cancer, including the approval of inavolisib and the growing importance of biomarker testing, is reshaping treatment strategies, patient care, and adverse event management.
EP. 1: Precision Pathways: Emerging Targeted Therapies in HR+/HER2- Breast Cancer
December 17th 2024Panelists discuss how emerging targeted therapies, including novel PI3K inhibitors and combination treatments, are advancing precision pathways in HR positive (HR+)/HER2 negative (HER2-) breast cancer, offering new hope for personalized treatment and improved patient outcomes.
EP. 2: INAVO120 Trial Insights and Inavolisib's Emerging Role in the Treatment Armamentarium
December 17th 2024Panelists discuss how the October 2024 FDA approval of inavolisib in combination with palbociclib and fulvestrant for HR positive (HR+)/ HER2 negative (HER2-) metastatic breast cancer with a PIK3CA mutation marks a pivotal advancement in precision medicine, highlighting how agents like such as inavolisib, capivasertib, elacestrant, and alpelisib have transformed treatment approaches and expanded therapeutic options for patients.
